Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Burzynski Clinic Presents Over Five Years Survival Data From Phase II Trials of ANP for Inoperable Brain Tumors at the Congress

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/16/2013 | 03:34am CET

The Burzynski Clinic (BC) announced today that it made a keynote speaker presentation at the 2nd Annual Congress of Asia-Pacific Academy of Anti-Aging Medicine in Beijing, China. Based on the presentation in Beijing, a total of 401 eligible patients (patients who received over 28 days of treatment) with advanced inoperable brain tumors have been treated with antineoplaston A10 and antineoplastons AS2-1 therapy (ANP) in phase II studies. Most of the patients (87%) were diagnosed with high-grade tumors and the remaining patients were diagnosed with low-grade tumors. The patients were diagnosed by pathologists not associated with BC and objective responses were verified by Central Radiology Review. The group of 77 patients (19%) survived over five years from the treatment start. Of particular interest were results in patients with brainstem gliomas. The group of 17 patients with brainstem glioma underwent the treatment and 65% of these patients survived over five years. An additional group of 42 patients diagnosed with diffuse intrinsic pontine glioma (DIPG) have been treated and a total of 19% survived over five years.

The quality of survival is very good and there is no long-term toxicity related to ANP.

These clinical results are very encouraging, since they describe a positive ANP effect on some of the worst malignancies in the entire oncology field, but they will require FDA approval.

Burzynski Clinic is committed to developing treatments for cancer based on genomic and epigenomic principles.

Forward-looking statements in this release are made pursuant to the safe harbor provisions of the federal securities laws. Information contained in forward-looking statements is based on current expectations and is subject to change, and future events may differ materially from those discussed herein due to a number of factors, including, but not limited to, risks and uncertainties related to the clinic's ability to use Antineoplastons A10 and AS2-1. Burzynski Clinic does not undertake to update any such forward-looking statements or to publicly announce developments or events relating to the matters described herein.

For Burzynski Clinic
Carolyn Powers, 713-335-5664
carolyn@burzynskiclinic.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
Date Title
08:31p Smart Inhalers Market Viewed As Key To Ensuring More Effective Healthcare Monitoring Remotely - MarketIntelReports
08:13p TRACTOR SUPPLY : Kerens Chamber cuts ribbon for Wings of Heaven's Gate
08:01p Super Tough Nylon Market Viewed As Key For Success Of Hybrid Injection Molding Technology - MarketIntelReports
07:56p OTD : March 25
07:51p OFFICE OF GOVERNOR OF STATE OF NEW YOR : White Supremacist Fliers Found in Lewiston, Investigation Begins
07:50p TRANSCANADA : Keystone approval spells headache for Canada's Trudeau
07:46p SACYR : Industrial signs the contract for a new cement plant in Bolivia for 241 million dollars
07:41p EMERSON ELECTRIC : U.S. Patents Awarded to Inventors in Missouri (March 25)
07:41p UNITED TECHNOLOGIES : Federal Contracts Awarded to Companies in Connecticut (March 25)
07:41p RAYTHEON : Federal Contracts Awarded by Federal Agencies in Alabama (March 25)
Latest news
Advertisement
Hot News 
9.35%Infineon raises 2017 outlook on stronger automotive orders
2.89%British engineer Smiths posts higher first-half profit, reaffirms FY outlook
-1.59%ANTHEM : Grilled as It Seeks to Save Cigna Deal
3.07%EXCLUSIVE - CHINA-BACKED FUND RELAUNCHES BID FOR U.S. CHIP DEAL APPROVAL : sources
7.57%TOSHIBA : shares rise 6 percent after Effissimo increases stake
Most Read News
03/24 TRANSCANADA : Trump administration approves controversial Keystone pipeline
03/24 K BRO LINEN : Bro Announces 2016 Annual Results and Positions the Company for Growth
03/24 TESLA : to take orders for solar roof tiles starting April
03/24 BRF : Brazil meat probe will show further evidence of graft - sources
03/24 CONOCOPHILLIPS : Company grants $118,000 to support community groups
Most recommended articles
03/21 UK to investigate any UK banking involvement in 'Laundromat' case
10:51aDJWAL MART STORES : Correction to Wal-Mart Buying Spree Irks Some Hipsters Article
10:49a APPLE : Chinese court rules in favour of Apple in local design patent disputes
10:27a TESCO : nearing deal with Serious Fraud Office over accounting scandal -Sky
08:53aDJMARKET SNAPSHOT : Stock Investors Will Be Asking 'where's The Beef' As Trump Suffers A Setback